Product Details
| Product Name:
Aplaviroc |
CAS No.:
461443-59-4 |
| Purity:
99.47% |
Supply Ability:
10g |
| Release date:
2026/04/27 |
Product Introduction
Bioactivity
| Name | Aplaviroc |
| Description | Aplaviroc (AK 602), an SDP derivative, is a CCR5 antagonist with IC50 values of 0.1-0.4 nM for HIV-1Ba-L, HIV-1JRFL, and HIV-1MOKW. |
| In vitro | Aplaviroc showed an IC50 value of 0.1 to 0.4 nM for the three wild-type R5 HIV-1 strains (HIV-1Ba-L, HIV-1JRFL, and HIV-1MOKW) and effectively blocked rgp120/sCD4 and CCR5 with an IC50 value of 2.7 nM; Aplaviroc inhibited the infectivity and replication of the two HIV-1MDR variants, HIV-1MM and HIV-1JSL, at very low concentrations (IC50 value 0.4 to 0.6 nM), while the two R5 HIV-1 variants inhibited zidovudine, nelfinavir, and nafenacil. Aplaviroc inhibits the infectivity and replication of the two HIV-1MDR variants, HIV-1MM and HIV-1JSL, at very low concentrations (IC50 values of 0.4 to 0.6 nM), resulting in AplavirocKd values of 2.9±1.0 nM, respectively; Aplaviroc's potent activity against R5 HIV-1 stems from its high-affinity binding to ECL2B and/or its neighboring regions, which leads to inhibition of the interaction between rgp120/CD4 and CCR5. gp120/CD4 binding to CCR5 [1]. |
| In vivo | The concentration of apraviroc (AK602) reaches maximum concentration immediately after intraperitoneal administration and decreases rapidly [2];Aplaviroc (AK602, 60 mg/kg, bid, daily) inhibits R5 HIV-1 viremia in hu-PBMC-NOG mice[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | HIVProtease | HIV-1MOKW | HIV-1JRFL | HIV-1Ba-L | HIV Protease | HIV | GW-873140 | GW873140 | GSK-873140 | GSK873140 | CCR5 | Aplaviroc | AK-602 | AK602 |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Emtricitabine | Dolutegravir intermediate-1 | Dimethyl fumarate | Lamivudine | Valproic Acid | (-)-Epigallocatechin Gallate | Pirfenidone | Decanedioic acid | Dextran sulfate sodium salt (MW 5000) | Tenofovir |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Drug-induced Liver Injury (DILI) Compound Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Infection Compound Library | Human Metabolite Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$545.00
|
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-04-27 |
United States